Skip to main content

Meet with our product experts in one-on-one virtual sessions

Set Up a Meeting
Quick Connect



CAS Number: 1108743-60-7

Therapeutic Category
Anti-Cancer/ Oncology
API Technology
Dose Form
Oral Solid/Capsules
Dr Reddy's Development Status
Innovator Brand (USA)

Mechanism of Action

Entrectinib is a selective tyrosine kinase inhibitor that acts by blocking the activity of specific abnormal proteins in cancer cells. It targets two proteins, TRKA and ROS1, which are frequently abnormal in various types of cancer and play a role in the growth and spread of these cancers. By inhibiting the activity of these proteins, entrectinib can slow down or stop the growth of cancer cells, and potentially shrink tumors.

TRKA is a receptor tyrosine kinase that is commonly altered in cancers such as lung cancer and neuroendocrine tumors. ROS1 is another receptor tyrosine kinase that is commonly altered in cancers such as non-small cell lung cancer, gastrointestinal stromal tumors, and cholangiocarcinomas.

Entrectinib is designed to target only the abnormal forms of these proteins, while having minimal impact on normal healthy cells. This targeted approach helps to minimize the side effects commonly associated with chemotherapy and other cancer treatments.


Entrectinib is a type of medication that is used in the treatment of solid tumors (such as non-small cell lung cancer (NSCLC), neuroendocrine tumors, and other types of cancer) that have a specific genetic alteration known as NTRK fusion.

Entrectinib works by blocking the activity of a protein called TRK, which is produced by the NTRK fusion gene and is involved in the development and growth of certain types of cancer. By blocking the activity of TRK, entrectinib helps to slow down the growth of cancer cells and can shrink the size of the tumor.

Dr. Reddy's Expertise

Headquartered in Hyderabad, India, Dr. Reddy's Laboratories is one of the leading Active Pharmaceutical Ingredients (API) manufacturers and suppliers globally for Entrectinib API. Dr. Reddy's API business is a preferred partner to pharma companies across the US, Europe, Brazil, Latin America, Japan, China, Korea, Middle East and other emerging markets.

Dr. Reddy's API business thrives on the deep technical strengths established over the last 30+ years in the development and manufacture of complex APIs such as steroids, peptides, complex long chain molecules and highly potent APIs (HPAPIs / oncology drugs). This expertise is complemented by our prowess in intellectual property and regulatory affairs which helps us consistently meet and exceed regulatory standards. Dr. Reddy's Entrectinib API is the outcome of the extensive expertise in R&D, IP, and Regulatory.

A key component in helping our customers be first to market is a responsive supply chain. We achieve this by making sure that all our facilities are operating efficiently and to the latest standards of quality, safety, and productivity. A strong interconnect between business and factories allows for a quick reaction to dynamic market changes, so that we can avert shortages and meet sudden surges in demand.

Oncology API Products:

Learn More

Contact Us

Please fill in the following form for API Requirement & we'll get back to you shortly

We are here to help, if you have any country specific requirements.


No information in this catalog - including any reference to any product or service - constitutes an offer for sale, or be construed as representing an offer for sale. Products protected under valid patents are not offered or supplied for commercial use. However, the research quantities of such products may be offered for the purpose of regulatory submissions, wherever such regulatory exemptions exist. The buyers should make their independent evaluation of the patent scenario for their respective markets and will be responsible for all patent related liabilities. Products protected under valid patents in India are not available for commercial use but would be available for Section 107A purposes.